A. Egorov

发表

236P Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1)

S. Hurvitz, E. Hamilton, G. Curigliano, 2022, Annals of Oncology.